A total of 608 participants with Clostridium Difficile Associated Diarrhea (CDAD) will
participate in this study; participants will receive either oral vancomycin or CB-183,315 in
a blinded fashion. Treatment will last for 10 days and participants will be followed up for
at least 40 days and a maximum of 100 days. The purpose of this study is to evaluate how well
CB-183,315 treats CDAD as compared to vancomycin.